WILMINGTON, Mass., March 12, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today its QS-H150 handheld explosives trace detector has received an important regulatory certification in China from the Chinese Ministry of Public Security. This marks the latest in a series of key product certifications for Implant Sciences, including STAC in France and TSA's qualification for air cargo screening in the US.
Implant Sciences has been active in the China market for several years. China represents an important market for the Company, one where it has generated over $20 million in sales to date. Its explosives trace detectors have been deployed at the 2008 Beijing Olympics, Beijing subway stations, and are in use for aviation security and critical infrastructure protection. In July 2013, the Company opened a representative office in Shanghai.
"This Ministry of Public Security certification opens the doors for us to compete for additional public security contracts issued by the Chinese government. We believe this will significantly expand our sales opportunities in China, where we already have a strong presence and our products have a stellar reputation for performance and cost efficiency," stated Glenn D. Bolduc, Implant Sciences' President and CEO.
Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones, added, "The results of these stringent certification tests further demonstrate the strength of our QS-H150. Notable accomplishments in the testing were the very rapid clear-down time, which is essential for high traffic screening areas, the large number and variety of explosives detected at minute levels, and the system's performance in a wide range of temperatures and environments."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. As of January 2013, the Company is only the third ETD manufacturer, and the first American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation